Audited Financial Results for the wquarter ended march31, 2026, recommendation and declaration of dividend , allotment of prefrential warrants
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals reported strong full-year FY2026 results with standalone revenue growing 74% to Rs 5,670.61 Lakhs from Rs 3,258.73 Lakhs in FY2025. Net profit after tax jumped 130% to Rs 2,204.79 Lakhs from Rs 957.51 Lakhs. However, Q4 FY2026 showed a standalone loss of Rs 172.67 Lakhs (vs profit of Rs 538.64 Lakhs in Q4 FY2025) due to high tax expenses of Rs 442.63 Lakhs including deferred tax adjustments. The Board recommended a final dividend of Re 0.01 per share (1%) for FY2025-26. The company allotted 17,35,000 equity shares to promoters Dakshesh Shah and Parshva Texchem India Pvt Ltd upon warrant conversion at Rs 25.50 per share, raising Rs 4.42 Crore. Cash position declined significantly from Rs 1,211.77 Lakhs to Rs 591.63 Lakhs due to heavy capital expenditure of Rs 1,573.02 Lakhs. Statutory auditors issued unmodified opinion with no concerns raised.
Strong annual performance with revenue and profit growth well above market expectations. The Q4 loss may cause short-term volatility, but positive operating cash flow of Rs 314.86 Lakhs and 74% revenue growth indicate healthy operations. Promoter warrant conversion signals confidence but increases promoter holding.